Bank of America Spends 250 Million Dollars Per Year on Weight-Loss Drugs for Employees

Bank of America revealed on Wednesday that it now spends approximately 250 million dollars annually providing GLP-1 weight-loss medications to its employees, a staggering figure that underscores the massive corporate embrace of drugs like Ozempic, Wegovy, and Mounjaro—and the financial burden employers are shouldering as a result.

The disclosure came during the bank's second-quarter earnings call, where CEO Brian Moynihan fielded questions about the company's rapidly escalating healthcare costs. The 250 million dollar price tag covers medications for tens of thousands of Bank of America employees and dependents enrolled in the company's health plans, making it one of the largest known corporate outlays for the new class of diabetes and obesity treatments.

GLP-1 drugs—glucagon-like peptide-1 receptor agonists—have exploded in popularity since 2024, driven by their remarkable effectiveness in promoting weight loss and improving metabolic health. Ozempic and Wegovy, both made by Novo Nordisk, along with Eli Lilly's Mounjaro and Zepbound, have become some of the most prescribed medications in America. But they come with a steep price: list prices often exceed $1,000 per month per patient.

Corporate America Grapples With Soaring Drug Costs

Bank of America is far from alone in wrestling with these expenses. Employers across the United States are experiencing double-digit increases in prescription drug spending as GLP-1 medications surge in utilization. Industry analysts estimate that corporate spending on these drugs could reach tens of billions of dollars annually by the end of the decade if current trends continue.

The issue has become so acute that some companies have begun limiting or eliminating coverage for weight-loss medications, even as others—like Bank of America—maintain broad access in the name of employee wellness. The bank's decision to continue covering GLP-1s reflects a growing belief that the long-term health benefits, including reduced risk of diabetes, heart disease, and other chronic conditions, may ultimately offset the upfront costs.

However, the math remains daunting. For a company with more than 200,000 employees, even a modest percentage using GLP-1 drugs can translate into hundreds of millions in annual expenses. Bank of America's 250 million dollar figure suggests that roughly 20,000 to 25,000 individuals covered under its health plans are receiving these medications—a penetration rate that mirrors broader national trends.

Pharma Giants See Windfall, Employers Demand Relief

The explosion in GLP-1 prescriptions has been a bonanza for Eli Lilly and Novo Nordisk, both of which reported blowout earnings in recent quarters fueled by insatiable demand. Eli Lilly raised its full-year outlook on Wednesday after Mounjaro and Zepbound sales crushed analyst expectations, while Novo Nordisk continues to struggle with supply shortages as it races to expand manufacturing capacity.

But the windfall for pharmaceutical companies has intensified pressure on employers and insurers to negotiate lower prices. Business coalitions and benefits consultants are pushing for value-based contracts, bulk discounts, and outcome-tied pricing arrangements that would tie reimbursement to sustained weight loss and health improvements rather than simple prescriptions filled.

Some companies are experimenting with tiered coverage models, requiring employees to meet certain health criteria or participate in lifestyle programs before gaining access to GLP-1 drugs. Others are turning to pharmacy benefit managers to secure discounts through formulary placement and rebate negotiations. Yet even with these strategies, the scale of spending remains unprecedented.

A Bellwether for the Future of Workplace Benefits

Bank of America's disclosure offers a rare glimpse into the hidden costs of the GLP-1 revolution. While the drugs have transformed obesity treatment and delivered meaningful health gains for millions of Americans, they have also upended the economics of employer-sponsored health insurance.

As more employees seek access to these medications—and as clinical indications expand beyond diabetes and obesity to include cardiovascular disease, sleep apnea, and other conditions—corporate spending is poised to climb even higher. Analysts predict that employers may soon face a choice: absorb unsustainable cost increases, shift more expenses to employees, or fundamentally rethink their approach to chronic disease management.

For now, Bank of America appears committed to maintaining coverage. But the 250 million dollar annual bill serves as a stark reminder that the GLP-1 era comes with a price—one that will reshape corporate benefits strategies, healthcare budgets, and the relationship between employers and pharmaceutical companies for years to come.